Search Results - "Van Abbema, Anne"

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma by van Rhee, Frits, Szmania, Susann M, Dillon, Myles, van Abbema, Anne M, Li, Xin, Stone, Mary K, Garg, Tarun K, Shi, JuMei, Moreno-Bost, Amberly M, Yun, Rui, Balasa, Balaji, Ganguly, Bishwa, Chao, Debra, Rice, Audie G, Zhan, Fenghuang, Shaughnessy, Jr, John D, Barlogie, Bart, Yaccoby, Shmuel, Afar, Daniel E H

“…Monoclonal antibody (mAb) therapy for multiple myeloma, a malignancy of plasma cells, has not been clinically efficacious in part due to a lack of appropriate…”
Get full text

Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection by Rappaport, Amy R., Hong, Sue-Jean, Scallan, Ciaran D., Gitlin, Leonid, Akoopie, Arvin, Boucher, Gregory R., Egorova, Milana, Espinosa, J. Aaron, Fidanza, Mario, Kachura, Melissa A., Shen, Annie, Sivko, Gloria, Van Abbema, Anne, Veres, Robert L., Jooss, Karin

“…The coronavirus disease 2019 (COVID-19) pandemic continues to spread globally, highlighting the urgent need for safe and effective vaccines that could be…”
Get full text

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma by Hsi, Eric D, Steinle, Roxanne, Balasa, Balaji, Szmania, Susann, Draksharapu, Aparna, Shum, Benny P, Huseni, Mahrukh, Powers, David, Nanisetti, Amulya, Zhang, Yin, Rice, Audie G, van Abbema, Anne, Wong, Melanie, Liu, Gao, Zhan, Fenghuang, Dillon, Myles, Chen, Shihao, Rhodes, Susan, Fuh, Franklin, Tsurushita, Naoya, Kumar, Shankar, Vexler, Vladimir, Shaughnessy, Jr, John D, Barlogie, Bart, van Rhee, Frits, Hussein, Mohamad, Afar, Daniel E H, Williams, Marna B

“…Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3 subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not…”
Get full text

A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors by Sohn, Sue J, Barrett, Kathy, Van Abbema, Anne, Chang, Christine, Kohli, Pawan Bir, Kanda, Hidenobu, Smith, Janice, Lai, Yingjie, Zhou, Aihe, Zhang, Birong, Yang, Wenqian, Williams, Karen, Macleod, Calum, Hurley, Christopher A, Kulagowski, Janusz J, Lewin-Koh, Nicholas, Dengler, Hart S, Johnson, Adam R, Ghilardi, Nico, Zak, Mark, Liang, Jun, Blair, Wade S, Magnuson, Steven, Wu, Lawren C

“…TYK2 is a JAK family protein tyrosine kinase activated in response to multiple cytokines, including type I IFNs, IL-6, IL-10, IL-12, and IL-23. Extensive…”
Get full text

Lead identification of novel and selective TYK2 inhibitors by Liang, Jun, Tsui, Vickie, Van Abbema, Anne, Bao, Liang, Barrett, Kathy, Beresini, Maureen, Berezhkovskiy, Leo, Blair, Wade S., Chang, Christine, Driscoll, James, Eigenbrot, Charles, Ghilardi, Nico, Gibbons, Paul, Halladay, Jason, Johnson, Adam, Kohli, Pawan Bir, Lai, Yingjie, Liimatta, Marya, Mantik, Priscilla, Menghrajani, Kapil, Murray, Jeremy, Sambrone, Amy, Xiao, Yisong, Shia, Steven, Shin, Young, Smith, Jan, Sohn, Sue, Stanley, Mark, Ultsch, Mark, Zhang, Birong, Wu, Lawren C., Magnuson, Steven

“…A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting…”
Get full text

Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors by Hanan, Emily J, van Abbema, Anne, Barrett, Kathy, Blair, Wade S, Blaney, Jeff, Chang, Christine, Eigenbrot, Charles, Flynn, Sean, Gibbons, Paul, Hurley, Christopher A, Kenny, Jane R, Kulagowski, Janusz, Lee, Leslie, Magnuson, Steven R, Morris, Claire, Murray, Jeremy, Pastor, Richard M, Rawson, Tom, Siu, Michael, Ultsch, Mark, Zhou, Aihe, Sampath, Deepak, Lyssikatos, Joseph P

“…The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2…”
Get full text

Lead Optimization of a 4‑Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors by Liang, Jun, van Abbema, Anne, Balazs, Mercedesz, Barrett, Kathy, Berezhkovsky, Leo, Blair, Wade, Chang, Christine, Delarosa, Donnie, DeVoss, Jason, Driscoll, Jim, Eigenbrot, Charles, Ghilardi, Nico, Gibbons, Paul, Halladay, Jason, Johnson, Adam, Kohli, Pawan Bir, Lai, Yingjie, Liu, Yanzhou, Lyssikatos, Joseph, Mantik, Priscilla, Menghrajani, Kapil, Murray, Jeremy, Peng, Ivan, Sambrone, Amy, Shia, Steven, Shin, Young, Smith, Jan, Sohn, Sue, Tsui, Vickie, Ultsch, Mark, Wu, Lawren C, Xiao, Yisong, Yang, Wenqian, Young, Judy, Zhang, Birong, Zhu, Bing-yan, Magnuson, Steven

“…Herein we report our lead optimization effort to identify potent, selective, and orally bioavailable TYK2 inhibitors, starting with lead molecule 3. We used…”
Get full text

Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors by Labadie, Sharada, Barrett, Kathy, Blair, Wade S., Chang, Christine, Deshmukh, Gauri, Eigenbrot, Charles, Gibbons, Paul, Johnson, Adam, Kenny, Jane R., Kohli, Pawan Bir, Liimatta, Marya, Lupardus, Patrick J., Shia, Steven, Steffek, Micah, Ubhayakar, Savita, Abbema, Anne van, Zak, Mark

“…A highly ligand efficient, novel 8-oxo-pyridopyrimidine containing inhibitor of Jak1 and Jak2 isoforms with a pyridone moiety as the hinge-binding motif was…”
Get full text

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2 by Labadie, Sharada, Dragovich, Peter S., Barrett, Kathy, Blair, Wade S., Bergeron, Philippe, Chang, Christine, Deshmukh, Gauri, Eigenbrot, Charles, Ghilardi, Nico, Gibbons, Paul, Hurley, Christopher A., Johnson, Adam, Kenny, Jane R., Kohli, Pawan Bir, Kulagowski, Janusz J., Liimatta, Marya, Lupardus, Patrick J., Mendonca, Rohan, Murray, Jeremy M., Pulk, Rebecca, Shia, Steven, Steffek, Micah, Ubhayakar, Savita, Ultsch, Mark, van Abbema, Anne, Ward, Stuart, Zak, Mark

“…Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an…”
Get full text

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu by Tai, Yu-Tzu, Dillon, Myles, Song, Weihua, Leiba, Merav, Li, Xian-Feng, Burger, Peter, Lee, Alfred I., Podar, Klaus, Hideshima, Teru, Rice, Audie G., van Abbema, Anne, Jesaitis, Lynne, Caras, Ingrid, Law, Debbie, Weller, Edie, Xie, Wanling, Richardson, Paul, Munshi, Nikhil C., Mathiot, Claire, Avet-Loiseau, Hervé, Afar, Daniel E.H., Anderson, Kenneth C.

“…Currently, no approved monoclonal antibody (mAb) therapies exist for human multiple myeloma (MM). Here we characterized cell surface CS1 as a novel MM antigen…”
Get full text

The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor by Schober, D A, Van Abbema, A M, Smiley, D L, Bruns, R F, Gehlert, D R

“…Recently, a novel high-affinity peptide antagonist, 1229U91, was published as a selective neuropeptide Y Y1 antagonist. The selectivity of 1229U91 was…”
Get full text

Anti-CSl humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu by TAI, Yu-Tzu, DILLON, Myles, VAN ABBEMA, Anne, JESAITIS, Lynne, CARAS, Ingrid, LAW, Debbie, WELLER, Edie, WANLING XIE, RICHARDSON, Paul, MUNSHI, Nikhil C, MATHIOT, Claire, AVET-LOISEAU, Hervé, WEIHUA SONG, AFAR, Daniel E. H, ANDERSON, Kenneth C, LEIBA, Merav, LI, Xian-Feng, BURGER, Peter, LEE, Alfred I, PODAR, Klaus, HIDESHIMA, Teru, RICE, Audie G

Get full text

Design and Discovery of N‑(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic by Ramurthy, Savithri, Taft, Benjamin R, Aversa, Robert J, Barsanti, Paul A, Burger, Matthew T, Lou, Yan, Nishiguchi, Gisele A, Rico, Alice, Setti, Lina, Smith, Aaron, Subramanian, Sharadha, Tamez, Victoriano, Tanner, Huw, Wan, Lifeng, Hu, Cheng, Appleton, Brent A, Mamo, Mulugeta, Tandeske, Laura, Tellew, John E, Huang, Shenlin, Yue, Qin, Chaudhary, Apurva, Tian, Hung, Iyer, Raman, Hassan, A. Quamrul, Mathews Griner, Lesley A, La Bonte, Laura R, Cooke, Vesselina G, Van Abbema, Anne, Merritt, Hanne, Gampa, Kalyani, Feng, Fei, Yuan, Jing, Mishina, Yuji, Wang, Yingyun, Haling, Jacob R, Vaziri, Sepideh, Hekmat-Nejad, Mohammad, Polyakov, Valery, Zang, Richard, Sethuraman, Vijay, Amiri, Payman, Singh, Mallika, Sellers, William R, Lees, Emma, Shao, Wenlin, Dillon, Michael P, Stuart, Darrin D

“…Direct pharmacological inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling,…”
Get full text

Abstract 724: A novel heterologous prime boost vaccine system drives tumor specific and potent CD8 T cell responses for cancer immunotherapy by Blair, Wade, Grotenbreg, Gijsbert, Scallan, Ciaran, Rappaport, Amy, Greer, Renee, Gitlin, Leonid, Lam, Kieu, Heyes, James, Abbema, Anne Van, Hanson, Hadley, Schreiner, Petra, Jooss, karin

“…Abstract Tumor-specific neoantigens (TSNAs) are present in a majority of tumor types and are key targets for T cells released by immune checkpoint blockade…”
Get full text

Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors by Kulagowski, Janusz J, Blair, Wade, Bull, Richard J, Chang, Christine, Deshmukh, Gauri, Dyke, Hazel J, Eigenbrot, Charles, Ghilardi, Nico, Gibbons, Paul, Harrison, Trevor K, Hewitt, Peter R, Liimatta, Marya, Hurley, Christopher A, Johnson, Adam, Johnson, Tony, Kenny, Jane R, Bir Kohli, Pawan, Maxey, Robert J, Mendonca, Rohan, Mortara, Kyle, Murray, Jeremy, Narukulla, Raman, Shia, Steven, Steffek, Micah, Ubhayakar, Savita, Ultsch, Mark, van Abbema, Anne, Ward, Stuart I, Waszkowycz, Bohdan, Zak, Mark

“…A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway…”
Get full text

Design and Discovery of N‑(2-Methyl-5′-morpholino-6′-((tetrahydro‑2H‑pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers by Nishiguchi, Gisele A, Rico, Alice, Tanner, Huw, Aversa, Robert J, Taft, Benjamin R, Subramanian, Sharadha, Setti, Lina, Burger, Matthew T, Wan, Lifeng, Tamez, Victoriano, Smith, Aaron, Lou, Yan, Barsanti, Paul A, Appleton, Brent A, Mamo, Mulugeta, Tandeske, Laura, Dix, Ina, Tellew, John E, Huang, Shenlin, Mathews Griner, Lesley A, Cooke, Vesselina G, Van Abbema, Anne, Merritt, Hanne, Ma, Sylvia, Gampa, Kalyani, Feng, Fei, Yuan, Jing, Wang, Yingyun, Haling, Jacob R, Vaziri, Sepideh, Hekmat-Nejad, Mohammad, Jansen, Johanna M, Polyakov, Valery, Zang, Richard, Sethuraman, Vijay, Amiri, Payman, Singh, Mallika, Lees, Emma, Shao, Wenlin, Stuart, Darrin D, Dillon, Michael P, Ramurthy, Savithri

“…RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need. The exquisite dependency on CRAF kinase in KRAS mutant…”
Get full text

Abstract 5379: Inhibition of ULK1/2-mediated autophagy augments antigen processing and presentation in STK11 mutant NSCLC by Schwager, Samantha C., Park, Eugene, Van Abbema, Anne, Guan, Yihong, Rosen, Connor, Cho, Sean, Black, Michael, Kurilyak, Inna, Jeffrey, Jenna, Fung, Juan Jose, Paprcka, Susan L., Fernandez-Salas, Ester

“…Abstract BACKGROUND: Inactivating mutations and deletions in STK11 are present in 9-20% of NSCLC and result in immunologically cold tumors that respond poorly…”
Get full text

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model by Liang, Jun, Van Abbema, Anne, Balazs, Mercedesz, Barrett, Kathy, Berezhkovsky, Leo, Blair, Wade S., Chang, Christine, Delarosa, Donnie, DeVoss, Jason, Driscoll, Jim, Eigenbrot, Charles, Goodacre, Simon, Ghilardi, Nico, MacLeod, Calum, Johnson, Adam, Bir Kohli, Pawan, Lai, Yingjie, Lin, Zhonghua, Mantik, Priscilla, Menghrajani, Kapil, Nguyen, Hieu, Peng, Ivan, Sambrone, Amy, Shia, Steven, Smith, Jan, Sohn, Sue, Tsui, Vickie, Ultsch, Mark, Williams, Karen, Wu, Lawren C., Yang, Wenqian, Zhang, Birong, Magnuson, Steven

“…[Display omitted] Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through…”
Get full text

Identification of C‑2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2 by Zak, Mark, Hurley, Christopher A, Ward, Stuart I, Bergeron, Philippe, Barrett, Kathy, Balazs, Mercedesz, Blair, Wade S, Bull, Richard, Chakravarty, Paroma, Chang, Christine, Crackett, Peter, Deshmukh, Gauri, DeVoss, Jason, Dragovich, Peter S, Eigenbrot, Charles, Ellwood, Charles, Gaines, Simon, Ghilardi, Nico, Gibbons, Paul, Gradl, Stefan, Gribling, Peter, Hamman, Chris, Harstad, Eric, Hewitt, Peter, Johnson, Adam, Johnson, Tony, Kenny, Jane R, Koehler, Michael F. T, Bir Kohli, Pawan, Labadie, Sharada, Lee, Wyne P, Liao, Jiangpeng, Liimatta, Marya, Mendonca, Rohan, Narukulla, Raman, Pulk, Rebecca, Reeve, Austin, Savage, Scott, Shia, Steven, Steffek, Micah, Ubhayakar, Savita, van Abbema, Anne, Aliagas, Ignacio, Avitabile-Woo, Barbara, Xiao, Yisong, Yang, Jing, Kulagowski, Janusz J

“…Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the…”
Get full text

Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2 by Zak, Mark, Mendonca, Rohan, Balazs, Mercedesz, Barrett, Kathy, Bergeron, Philippe, Blair, Wade S, Chang, Christine, Deshmukh, Gauri, DeVoss, Jason, Dragovich, Peter S, Eigenbrot, Charles, Ghilardi, Nico, Gibbons, Paul, Gradl, Stefan, Hamman, Chris, Hanan, Emily J, Harstad, Eric, Hewitt, Peter R, Hurley, Christopher A, Jin, Tian, Johnson, Adam, Johnson, Tony, Kenny, Jane R, Koehler, Michael F. T, Bir Kohli, Pawan, Kulagowski, Janusz J, Labadie, Sharada, Liao, Jiangpeng, Liimatta, Marya, Lin, Zhonghua, Lupardus, Patrick J, Maxey, Robert J, Murray, Jeremy M, Pulk, Rebecca, Rodriguez, Madeleine, Savage, Scott, Shia, Steven, Steffek, Micah, Ubhayakar, Savita, Ultsch, Mark, van Abbema, Anne, Ward, Stuart I, Xiao, Ling, Xiao, Yisong

“…Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1…”
Get full text